Notable Labs

Personalized drug discovery for blood cancer.

notablelabs.com

HQ: Foster City, CA, USA

11-50

Healthcare

Company research

Public company, workplace, funding, and market signals

Updated Jul 29, 2026

Overview

Notable Labs was a Foster City, California–based clinical-stage platform therapeutics company focused on predictive precision medicine for hematologic cancers. Its main platform, PPMP, used ex vivo testing plus software/automation to predict which drug or drug-combination was most likely to work for a given patient. The company later entered Chapter 7 bankruptcy in October 2024 and its assets were slated for liquidation.

Primary product

Predictive Precision Medicines Platform (PPMP)

Founded

2014

Headquarters

320 Hatch Dr, Foster City, California 94404, USA

Team size

1-10

Industry

Biotechnology Research

Sub-industry

Clinical-stage platform therapeutics / precision oncology

Offices

Foster City, California, United States

Business model

platform therapeutics

drug discovery and development

clinical testing services

biopharma co-development

licensing / in-licensing

Funding

Stage

public

Total raised

$72.2M

Latest round

Private placement / pre-merger financing · Oct 2023

Latest amount

$10.3M

Private placement / pre-merger financing

Oct 2023 · Builders VC

$10.3M

Series B

Jul 2019 · B Capital Group and LifeForce Capital

$40M

Series A

Sep 2017 · Builders VC

$10M

Seed convertible notes

Jan 2014

$7M

People & investors

Leadership

Thomas A. Bock, MD, MBA

Chief Executive Officer (former; Feb 2021-Aug 2024)

Joseph Wagner

Chief Scientific Officer (former; through Oct 2024)

Kaile A. Zagger

Interim Chief Executive Officer & Chief Restructuring Officer (former; Sep 2024-Mar 2025)

Founders

Matthew De Silva

Founder; former CEO / Executive Chairman

Pete Quinzio

Co-founder; former COO/CFO/board member

Peter Quinzio

Founder; Chief Operating Officer; Chief Financial Officer; Board Member

Investors

Accelerate Brain Cancer Cure

Lightspeed Venture Partners

Upside Partnership

Y Combinator

Work & culture

Mission-driven and science-focused; the company publicly emphasized 'mission over ego,' scientific responsibility, perseverance with compassion, relentless resourcefulness, respect, safety, and inclusivity.

Compensation

No public salary bands or compensation details were found in accessible sources; public job listings were visible but did not expose pay ranges.

Product & market

Differentiators

—Predictive Precision Medicines Platform (PPMP) that bio-simulates treatment response ex vivo
—focus on hematologic cancers and patient-sample functional testing
—automation plus AI-driven translational workflow
—drug-combination testing against a patient’s own cancer cells
—platform-guided patient selection for clinical development
—in-licensing / triple-de-risked development strategy

Technology

Ruby/Rails

Python

Django

React

GraphQL

TypeScript

AWS

Docker

Git

Jupyter

Tableau

RDS

DynamoDB

Customers

relapsed/refractory hematologic cancer patients

oncologists and treating physicians

academic medical centers

biopharma partners

Competitors

OctreoPharm Sciences

Isoma Diagnostics

Abscint

Exsegen

CHT Canada Health Technology

Scale & contact

Estimated revenue

US$1M-$10M

Estimated monthly visits

131

info@notablelabs.com 408-713-1104

Signals & risks

Layoff

Sep 2024

Reportedly cut 65% of its workforce and paused a clinical trial.

Source

Other

Oct 2024

Filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware; assets to be liquidated and board/executives departed.

Source

Other

Oct 2024

External coverage confirmed the bankruptcy and stated that development of the Boehringer Ingelheim-licensed volasertib program was ending.

Source

Other

Mar 2025

Nasdaq delisting determination became final; shares were removed from listing effective March 17, 2025.

Source

Latest news

Notable goes bankrupt, ending plans for Boehringer cancer drug

Fierce Biotech · Oct 2024

Reported Chapter 7 bankruptcy, liquidation plans, and the end of the volasertib program.

Cancer-focused Notable Labs layoffs: 65% of workforce cut

San Francisco Business Times · Sep 2024

Reported 65% layoffs and a paused clinical trial amid financial strain.

Notable Labs pauses implementation of cancer drug volasertib study, announces layoffs

SEC filing · Sep 2024

Board approved a streamlined operating plan, paused Phase 2 volasertib work, and cut workforce/consultants by about 65%.

Notable Labs Announces CEO Transition

Nasdaq / GlobeNewswire · Aug 2024

Thomas A. Bock resigned as CEO and board member; Joseph Wagner was named interim CEO.

Notable Labs Receives FDA Clearance to Proceed Further with Volasertib Phase 2 Study

BioSpace / GlobeNewswire · Jul 2024

FDA clearance and dosing-plan agreement moved the company's Phase 2 volasertib study for relapsed/refractory AML toward enrollment.

Jobs and careers at Notable Labs

11 jobs at Notable Labs

Engineering Manager

Remote

Engineering

San Mateo, CA; San Mateo, California, USA

1w ago

Remote

Full-time